So far our outlook has proven astute, as we advised readers to be continue to be involved in the precious metals as the best hedge in the mounting global debt crisis, which is far from over. Gold has hit a new high this week, and is likely to continue higher -- with periodic pullbacks. But this week, even more action indicates that the European debt crisis is metastisizing and likely to spread to other markets.
The U.S. approval of a new debt ceiling has taken a back seat to some important developments in key markets.The warning signs include the following:
* The Swiss Franc spiking to all-time highs against the dollar and other currencies
* 30-year Treasury bond yield dropping to under 4%.
* All European bonds being sold
* Gold hitting new highs.
The markets are telling you something. Personally I have gone to a much higher cash position, and I have bought more gold and silver as protection against mounting currency devaluation. I also believe there are certain places to hide such as high-yielding energy, dividend, and biotech stocks.
As a reminder, in March, Investor Uprising launched a premium investment newsletter service that gives you access to our best ideas and detailed research. Investor Uprising Confidential (IU Confidential) published an important report, "All That Glitters: The Ultimate Gold Report," which told you why at $1,450 gold was still undervalued and likely to go much higher. Gold traded today as high as $1,646.The report tells you why this is likely to be only a way-station to much higher prices.
IU Confidential also completed some detailed research on the Biotech market, which shows that it can be a "place to hide." The biotech market, as measured by leading biotech indices, did not lose as much during the 2008 financial crisis -- and when it bounced back, the performance was much better than the leading indices. In other words, Biotech has outperformed the S&P 500 with less risk during the last five years.
Our research indicates this is likely to continue. You can still get both of these reports individually -- or subscribe to the service and get both of them plus five more bi-monthly reports for the next 12 months.
As a Rayno Report reader, this research is available to you at an exclusive low price. Click below for these exciting offers:
The Best of Biotech -- $399 Special (Regular $500)
The Ultimate Gold Report -- $299 Special (Regular $500)
(Includes The Ultimate Gold report, Best of Biotech Report + 5 more reports over the next 12 months!) -- $999 Special (regular $1250.